Skip to search formSkip to main contentSkip to account menu

Androgen Receptor Inhibitor EPI-506

Known as: AR Inhibitor EPI-506, EPI-506 
An orally bioavailable, small molecule inhibitor of the N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

4 relations
AR protein, humanInhibition of Cell ProliferationNegative Regulation of Receptor ActivationTranslational Repression

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.
220 Background: EPI-506, pro-drug of EPI-002, was a first-in-class oral small molecule from the Aniten family of compounds, which… 
Review
2016
Review
2016
Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
Androgen receptor (AR) has been a main target in prostate cancer therapy. The exhausting battle against AR mutation or splicing… 
2016
2016
Analysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with…
TPS5030Background: Androgen receptor (AR) signaling remains essential for CRPC progression and current inhibitors, such as… 
2015
2015
A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression…
TPS5072 Background: EPI-506 is a first-in-class, highly specific small molecule inhibitor of the androgen receptor (AR) N… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)